Technical Analysis for UNVC - Univec, Inc
Quote Chart
Technical Analysis for UNVC - Univec, Inc
Quote Chart End-of-Day Signals Profile Buy or Sell? News & Commentary Indicators Fundamentals
Grade Last Price % Change Price Change
A 0.064 33.33% 0.0160
UNVC closed up 33.33 percent on Monday, January 25, 2021, on 1.83 times normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Trend Table & Recent EOD Signals
ADX Long Term Intermediate Term Short Term
Very Strong Up Up Up
Date Alert Name Type % Chg
Jan 25 New 52 Week Closing High Bullish 0.00%
Jan 25 Expansion Breakout Bullish Swing Setup 0.00%
Jan 25 Wide Range Bar Range Expansion 0.00%
Jan 25 New 52 Week High Strength 0.00%
Jan 25 Wide Bands Range Expansion 0.00%
Jan 25 Above Upper BB Strength 0.00%
Jan 25 Overbought Stochastic Strength 0.00%
Jan 25 Upper Bollinger Band Touch Strength 0.00%
Jan 22 1,2,3 Pullback Bullish Bullish Swing Setup 33.33%
Jan 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 33.33%
Profile
Company Homepage
UNVC on Yahoo! Finance
UNVC on TradingView
Univec, Inc. (Univec), is an integrated licensing, manufacturing, and marketing company operating two divisions dedicated to providing safer health products to patients and caregivers worldwide. The Company’s syringe division develops, licenses and markets auto-disable and safety syringes worldwide. The physician and pharmaceutical services division assists pharmaceutical companies in marketing, fulfillment and tracking drug samples via an online system connecting pharmacies and managed payment providers. The Company also manufactures and markets sliding sheath syringes designed to protect patients and healthcare workers from needle stick injuries, in compliance with the federal needlestick safety and prevention act of the United States government.
Classification
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC
Is UNVC a Buy, Sell or Hold?
Indicators
Indicator Value
52 Week High 0.066
52 Week Low 0.0045
Average Volume 3,024,478
200-Day Moving Average 0.0240
50-Day Moving Average 0.0259
20-Day Moving Average 0.0360
10-Day Moving Average 0.0474
Average True Range 0.0067
ADX 55.63
+DI 39.6588
-DI 6.7164
Chandelier Exit (Long, 3 ATRs ) 0.0459
Chandelier Exit (Short, 3 ATRs ) 0.0346
Upper Bollinger Band 0.0629
Lower Bollinger Band 0.0091
Percent B (%b) 1.02
BandWidth 149.4444
MACD Line 0.0088
MACD Signal Line 0.0068
MACD Histogram 0.002
Fundamentals Value
Market Cap 11.6 Million
Num Shares 181 Million
EPS -0.01
Price-to-Earnings (P/E) Ratio -6.40
Price-to-Sales 1.76
Price-to-Book 0.00
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0925
Resistance 3 (R3) 0.0900 0.0780 0.0878
Resistance 2 (R2) 0.0780 0.0707 0.0793 0.0862
Resistance 1 (R1) 0.0710 0.0663 0.0745 0.0735 0.0846
Pivot Point 0.0590 0.0590 0.0608 0.0603 0.0590
Support 1 (S1) 0.0520 0.0517 0.0555 0.0545 0.0434
Support 2 (S2) 0.0400 0.0473 0.0413 0.0418
Support 3 (S3) 0.0330 0.0400 0.0403
Support 4 (S4) 0.0355
https://otcbb.swingtradebot.com/equities/UNVC:OTC
TOODLES
3
Scroll down for more posts ▼
Top 10 Most Recent News Articles
First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...
Continue Reading
A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...
Continue Reading
Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...
Continue Reading
Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...
Continue Reading
Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...
Continue Reading
Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...
Continue Reading
A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...
Continue Reading
AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...
Continue Reading
Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...
Continue Reading
A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...
Continue Reading
Top 5 Most Recently Viewed Articles
Chart Industries Announces Leadership Change Chart Industries (NYSE: GTLS) is taking significant steps toward a future transition as CEO Jill Evanko has announced plans to assume a senior advisor role starting in early 2026. This change comes as she prepares to take on a new executive opportunity within a privately owned company. Evanko has been essential in steering the...
Continue Reading
Understanding Debtors: Key Insights from Realkredit Danmark A/S At the heart of any effective financial institution is a reliable understanding of its debtors. Realkredit Danmark A/S, a prestigious name in the financial landscape, recently made available a detailed breakdown of its debtors. This information is crucial for various stakeholders, including investors,...
Continue Reading
Bitcoin's Recent Performance The cryptocurrency market has been lively lately, especially with Bitcoin recently falling below the $59,000 threshold. Investors had been optimistic, especially since the cryptocurrency saw a remarkable $436 million in net ETF inflows just last week. This significant influx signals that institutional interest in cryptocurrencies is still...
Continue Reading
Introduction to The Emily Program and ARFID The Emily Program is making significant strides in specialized care for individuals with Avoidant/Restrictive Food Intake Disorder (ARFID). This condition, often misunderstood, has recently begun to garner more attention from healthcare experts. In response to this need, The Emily Program is offering advanced treatment...
Continue Reading
Overview of Legal Actions Against 3D Systems Corporation Recently, investors in 3D Systems Corporation have found themselves entangled in a potential securities fraud lawsuit. This case serves as a cautionary tale, highlighting the importance of transparency and integrity in corporate communication. The allegations stem from assertions that the company made misleading...
Continue Reading